{"result": "(\"entity\"<|>GÁSTRICO<|>EVENT<|>Gástrico is a type of tumor associated with significant weight loss in patients, with 85% experiencing weight loss of more than 10% in the six months prior to diagnosis.)\n##\n(\"entity\"<|>PÁNCREAS<|>EVENT<|>Páncreas is a type of tumor linked to weight loss, with 83% of patients losing more than 10% of their weight before diagnosis.)\n##\n(\"entity\"<|>PULMÓN NO MICROCÍTICO<|>EVENT<|>Pulmón no microcítico is a type of lung cancer where 61% of patients experience significant weight loss prior to diagnosis.)\n##\n(\"entity\"<|>PULMÓN MICROCÍTICO<|>EVENT<|>Pulmón microcítico is a type of lung cancer with 57% of patients reporting weight loss exceeding 10% before diagnosis.)\n##\n(\"entity\"<|>PRÓSTATA<|>EVENT<|>Próstata is a type of cancer where 56% of patients experience weight loss of more than 10% in the six months leading up to diagnosis.)\n##\n(\"entity\"<|>COLON<|>EVENT<|>Colon cancer is associated with 54% of patients experiencing significant weight loss prior to diagnosis.)\n##\n(\"entity\"<|>LINFOMA ALTO GRADO<|>EVENT<|>Linfoma alto grado is a type of lymphoma where 48% of patients report weight loss exceeding 10% before diagnosis.)\n##\n(\"entity\"<|>SARCOMAS<|>EVENT<|>Sarcomas are tumors where 39% of patients experience significant weight loss prior to diagnosis.)\n##\n(\"entity\"<|>LEUCEMIA AGUDA NO LINFOBLÁSTICA<|>EVENT<|>Leucemia aguda no linfoblástica is a type of leukemia with 39% of patients experiencing weight loss of more than 10% before diagnosis.)\n##\n(\"entity\"<|>MAMA<|>EVENT<|>Mama cancer is associated with 36% of patients experiencing significant weight loss prior to diagnosis.)\n##\n(\"entity\"<|>LINFOMA BAJO GRADO<|>EVENT<|>Linfoma bajo grado is a type of lymphoma where 10% of patients report weight loss exceeding 10% before diagnosis.)\n##\n(\"relationship\"<|>GÁSTRICO<|>PÁNCREAS<|>Both Gástrico and Páncreas are types of tumors associated with significant weight loss in cancer patients, indicating a relationship in their impact on patient health.<|>7)\n##\n(\"relationship\"<|>PULMÓN NO MICROCÍTICO<|>PULMÓN MICROCÍTICO<|>Both Pulmón no microcítico and Pulmón microcítico are types of lung cancer linked to weight loss, suggesting a commonality in their effects on patients.<|>7)\n##\n(\"relationship\"<|>PRÓSTATA<|>COLON<|>Both Próstata and Colon cancers are associated with significant weight loss in patients, indicating a relationship in their impact on health outcomes.<|>6)\n##\n(\"relationship\"<|>LINFOMA ALTO GRADO<|>SARCOMAS<|>Both Linfoma alto grado and Sarcomas are types of cancers that can lead to significant weight loss, indicating a relationship in their effects on patients.<|>5)\n##\n(\"relationship\"<|>LEUCEMIA AGUDA NO LINFOBLÁSTICA<|>MAMA<|>Both Leucemia aguda no linfoblástica and Mama cancers are associated with significant weight loss in patients, indicating a relationship in their impact on health outcomes.<|>5)\n##\n(\"relationship\"<|>LINFOMA BAJO GRADO<|>GÁSTRICO<|>Both Linfoma bajo grado and Gástrico are types of tumors that can lead to weight loss, indicating a relationship in their effects on patients.<|>4)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ida de peso según el tipo de tumor |||||\n|---|---|---|---|---|\n| Tumor | Nº enf | Pérdida de peso los 6 meses previos al diagnóstico (%) |||\n|||1-5%|5-10%|>10%|Total|\n|Gástrico|317|21|31|33|85 %|\n|Páncreas|111|29|28|26|83 %|\n|Pulmón no microcítico|590|25|21|15|61 %|\n|Pulmón microcítico|436|23|20|14|57 %|\n|Próstata|78|28|18|10|56 %|\n|Colon|307|26|14|14|54 %|\n|Linfoma alto grado|311|20|13|15|48 %|\n|Sarcomas|189|21|11|7|39 %|\n---\n| Leucemia aguda no linfoblástica | 129 | 27 | 8 | 4 | 39 % |\n|--------------------------------|-----|----|----|---|------|\n| Mama | 289 | 22 | 8 | 6 | 36 % |\n| Linfoma bajo grado | 290 | 14 | 8 | 10 | 10 % |\n\n## 2.- FACTORES QUE INTERVIENEN EN LA PÉRDIDA DE PESO DEL ENFERMO DE CÁNCER\n\n1. Causas locales que alteran la fisiología del tubo digestivo. Dependerán de la localización del tumor (p. ej.: dolor con la ingesta en tumores de cabeza y cuello, obstrucción intestinal o malabsorción en tumores intestinales).\n\n2. Alteraciones metabólicas debidas a la propia enfermedad: producción de citoquinas (TNF-α, factor de necrosis tumoral), alteraciones del metabolismo de la glucosa (disminución de la sensibilidad a la insulina, aumento de la gluconeogénesis), de los lípidos (aumento de oxidación de ácidos grasos, hiperlipemia) y de las proteínas (disminución de síntesis proteica y balance nitrogenado negativo).\n\n3. Causas relacionadas con el paciente: ansiedad, depresión, miedo, cambio estético o incapacidad para cocinar.\n\n4. Tratamientos. Las alteraciones nutricionales suelen ser mayores con los tratamientos combinados.\n\n   - Cirugía. La cirugía del tracto digestivo es la que mayor probabilidad tiene de producir alteraciones en el estado nutricional del paciente. Los mecanismos se exponen en la tabla 2.\n\n   - Radioterapia. Depende de la localización, extensión, dosis y fraccionamiento así como de los tratamientos previos y su combinación con quimioterapia. Los efectos aparecen en las dos primeras semanas, alcanzando el máximo al superar las dos terceras partes de la dosis, suelen desaparecer de dos a cuatro semanas tras la finalización. Algunos síntomas pueden ser subagudos o crónicos (pueden tardar varios meses en desaparecer o mantenerse indefinidamente), como la xerostomía, la pérdida de sabor, la osteoradionecrosis mandibular, fibrosis muscular o malabsorción. Como efectos agudos, los más frecuentes son la mucositis, enteritis, proctitis, diarrea y la cistitis.\n\n   - Quimioterapia. Su efecto varía en función del fármaco, del esquema de tratamiento, la dosis, la duración y la susceptibilidad individual. Los efectos secundarios que pueden afectar al estado nutricional son: náuseas, vómitos, dis/hipogeusia, mucositis, diarrea, infecciones, íleo, estreñimiento, anorexia y xerostomía. Son de corta duración y suelen recuperarse con la interrupción del tratamiento. Respecto a los nuevos tratamientos biológicos hay variedad,\n\n158\n---\nLos anticuerpos monoclonales tienen escasa toxicidad gastrointestinal pero los inhibidores de tirosin-kinasa, se acompañan de anorexia, diarrea y náuseas.\n\n| Tabla 2. Alteraciones de la cirugía oncológica causantes de desnutrición |\n|-----------------------------------------------------------------------|\n| Área quirúrgica | Alteraciones |\n|-----------------|---------------|\n| Cabeza y cuello | Masticación. Deglución. Xerostomía. Disfagia motora o mecánica. Fístulas. |\n| Esófago | Trastornos deglución. Reflujo. Plenitud. Saciedad precoz. Estenosis. Fístulas. |\n| Estómago | Saciedad precoz. Síndrome dumping. Malabsorción de: vitamina B12, hierro, calcio. Intolerancia láctea |\n| Intestino delgado | Diarrea. Alteraciones hidroelectrolíticas, Intolerancia lactosa. Malabsorción de: vitaminas liposolubles, B12, calcio, hierro, zinc. Estenosis. F\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}